Mouse study could provide foundation for future human therapeutics
Supplementing a single protein found in the spinal cord could help prevent symptoms of Lou Gehrig’s disease, according to a new study out of Case Western Reserve University School of Medicine. Researchers found high levels of the protein—called mitofusion 2 or Mfn2—prevented nerve degeneration, muscle atrophy, and paralysis in a mouse model of the disease. Since Mfn2 is often depleted during Lou Gehrig’s, the new study suggests supplementing it could be a novel therapeutic approach for the disease.
Lou Gehrig’s disease, or amyloid lateral sclerosis (ALS), is a progressive disorder that devastates motor nerve cells. People with ALS slowly lose the ability to control muscle movement, and are ultimately unable to speak, eat, move, or breathe. The cellular mechanisms behind ALS are also found in certain types of dementia. For the estimated 15,000 Americans living with ALS, the findings offer new hope for ways to delay symptoms.
“We found a way to alleviate age and ALS-related muscular atrophy in our mouse models,” said Xinglong Wang, PhD, associate professor of pathology at Case Western Reserve University School of Medicine. “Amazingly, we could delay ALS symptom onset by 67 days.”
Wang led the study, recently published in Cell Metabolism, in which researchers successfully staved off muscle atrophy and paralysis simply by increasing Mfn2 levels in mouse spinal cords.
Wang and colleagues tested the most widely used ALS mouse model. They genetically engineered the diseased mice to have increased Mfn2 levels—but only in nerve cells that extend from the spinal cord and connect to muscle fibers. In late stages of the disease, mice with high Mfn2 levels in these nerves were a healthy weight, and did not have any of the muscle atrophy, gait abnormalities, or reduced grip strength that mice in control groups developed. Even mice who underwent heavy sciatic nerve damage benefited from elevated Mfn2 levels.
Said Wang, “Upregulation of Mfn2 specifically in nerve cells is sufficient to abolish skeletal muscle loss in ALS and aged mice, despite ALS-causing protein being found in all organs and tissues.”
By studying nerve cells collected from the mice, Wang’s team uncovered how Mfn2 offers its protective effects. The researchers found Mfn2 coexists with nutrients in cell structures called mitochondria. Their experiments showed mitochondria travel along nerve cell extensions—axons—and deliver the nutrients to the point where nerve cells and muscle fibers meet. This preserves sensitive connections—synapses—between nerve and muscle cells and prevents muscle atrophy. “We found mitochondria function as miniature ‘trucks’ to transport protein along axons to prevent synaptic degeneration,” explained Wang.
Cellular transport is not typically in the job description for mitochondria. The ancient cellular structures are well-known to be “powerhouses of the cell”—producing energy that keeps cells running. According to Wang, “this is a novel, previously unrecognized role for mitochondria.”
Specifically, Wang’s team found mitochondria use Mfn2 on their surfaces to carry a nutrient called calpstatin. Calpstatin inhibits harmful enzymes that break down nerves and muscle fibers. With the help of Mfn2, mitochondria carry calpstatin along nerve cells axons to meet muscle cells. There, calpstatin prevents enzymes from destroying delicate synapse connections. But without Mfn2, mitochondria can’t carry the nutrient.
According to Wang, the findings have broad implications. “Mfn2 deficiency or mutations are commonly observed in patients with ALS, peripheral neuropathy, Alzheimer’s disease, and other neurodegenerative diseases in which synaptic loss has long been recognized as a prominent early feature,” he says. “Supplementing Mfn2 may be a common and effective therapeutic approach to treat a wide range of diseases including but not limited muscular disorders, patients with nerve injury and various major neurodegenerative diseases associated with synaptic loss.”
The Latest on: Lou Gehrig’s Disease
via Google News
The Latest on: Lou Gehrig’s Disease
- Jeremy Williams and family still living with ALS, still inspiring otherson May 11, 2020 at 3:08 pm
And as he watched Jeremy Williams struggle with movement and speech while coaching up the Greenville Patriots, Camp couldn’t help but wonder how much longer Williams had lived after that 2010 season ...
- Farmingdale Mom Battling ALS Encourages Social Media Challengeon May 8, 2020 at 1:36 pm
The 40-year-old mom of three has Lou Gehrig's disease but hopes a social media challenge raises awareness for an in-progress therapy.
- Be active against ALS in Ann Arbor this monthon May 8, 2020 at 9:30 am
May is ALS awareness month so Ann Arbor Active Against ALS has challenged the community to be active against Lou Gehrig’s Disease, also known as ALS. Throughout May, members of the community are ...
- Obituaries: Ann M. Donatoon May 7, 2020 at 4:12 pm
One of your neighbors posted in Obituaries. Click through to read what they have to say. (The views expressed in this post are the author’s own.) ...
- Researchers discover key mechanism of cytokine storm in Castleman diseaseon May 7, 2020 at 1:02 pm
When Castleman Disease patients have a flare of their symptoms, they experience a cytokine storm inside their bodies—a hyper-response from the immune system that can cause a fever, organ failure, and ...
- Resilience to ALS Due to Synaptic Safety Mechanismon May 6, 2020 at 5:34 pm
UCSF researchers have identified a powerful self-corrective mechanism within synapses that is activated by neurodegeneration and acts to slow down disease progression in animal models of ALS.
- A Nebraska man was diagnosed with ALS in January. His family shares how they've had to cope with the terminal disease at home.on May 4, 2020 at 10:26 am
Nebraska professor Chad McBride was diagnosed with ALS in January. His condition has forced his husband, Allen, to be a caregiver to both McBride and their 4-year-old son, Jackson. Because of the ...
- This day in sports: Yankees great Lou Gehrig ends his ironman streakon May 2, 2020 at 5:10 am
Lou Gehrig took himself out of the New York Yankees' starting lineup on this date in 1939, against the Detroit Tigers at Briggs Stadium, telling manager Joe McCarthy that he was “doing it for the good ...
- This Day in Yankees History: Lou Gehrig Plays 2,130th Consecutive Game Before Retiringon April 30, 2020 at 5:16 pm
Yankees legend Lou Gehrig played the final game of his historic streak on this day in 1939, appearing in his 2,130th contest in a row.
via Bing News